By Tessa Kraus
For years, our culture has promoted an endless loop of weight loss tips, new miracle detox teas and diets that quite never seem to work. These popular diet methods, which often don’t work as expected, have trapped Americans in a cycle of trial and disappointment. But now, there seems to be a magic fix: Glucagon-like peptides. GLP-1, a fast-acting drug, has taken America by storm, inviting people to try again to reach their weight loss goals.
GLP-1 drugs are a class of medications used to treat type 2 diabetes and obesity. Commonly known as Ozempic, Mounjaro and Zepbound, these weekly injections help stimulate your pancreas to produce more insulin to better regulate blood sugar. In turn, the drugs curb hunger by slowing digestion, helping your body feel full faster and satiated longer. As a result, this process can lead to drastic weight loss.
Beyond glucose control, Ozempic has improved the quality of life of people with type 2 diabetes. Users have noted increased enjoyment of cardiovascular activities that were once a struggle and higher energy levels. Because of the high glucose levels in their blood vessels, those with type 2 diabetes face an increased risk of heart disease complications. Ozempic offers cardiovascular protection, reducing the risk of stroke and heart attacks. A study found that individuals taking GLP-1 for three years experienced a 20% decrease in strokes, heart attacks and deaths. The powerful effects of these injections have proved to be positive for many Americans who have struggled to get their health under control.
But the question remains, how did these peptide drugs used to treat type 2 diabetes find their way into the homes of millions of Americans just like over-the-counter drugs like Tylenol, Claritin and NyQuil? One answer lies in how normalized these drugs have become solely for the purpose of weight loss. Nearly 38% of Americans, roughly 11 million people, reported taking Ozempic-type drugs for losing weight, and face no chronic health conditions, a KFF poll found. Celebrities like Oprah Winfrey, Lizzo and Rosie O’Donnell have praised their positive experiences with these drugs. Former professional tennis player Serena Williams is now collaborating with Ro, a telehealth company, to promote the use of GLP-1s. The surge of celebrity endorsements and advertisements has now blurred the line between genuine medical treatment and a glamorized promotion of magical weight loss.
Unlike traditional paid endorsements, influencers who promote Ozempic share their personal experiences and success stories. This enables the advertisement to appear genuine and trustworthy. In addition to their celebrity partnerships, GLP-1 medications have always included a subtitle about weight loss in their advertisements, knowingly piquing the ears of millions who have been trapped in a failed cycle of their own.
As a result of the increased intake of these GLP-1s, the food industry has seen a big shift in consumer behavior. Because the drug acts as an appetite suppressant, Walmart’s U.S. CEO John Furner told Bloomberg in 2023 that they see individuals who are taking these drugs are purchasing “less units of food, less calories.” These patterns are mirrored in statistical data. According to a UC Davis study, “Individuals taking GLP1s consume 55% more fruits and vegetables, 65% fewer sugary drinks, and 62% less alcohol.” Changes in consumer habits could have both positive and negative effects on the agricultural and beverage industries. Overall, strategies must be formulated to keep up with these growing trends and changes in consumer behavior.
GLP-1s will continue to redefine weight loss in America, forcing us to confront questions about discipline, health and our growing reliance on quick fixes. Aggressive marketing continues to push GLP-1 drugs out of the medical sphere and into the public eye as a cure for failed weight loss attempts. As the line between treatment and trend continues to blur, the normalization will only increase. One thing is for certain: these new drugs will continue to leave an impact on society’s relationship with the food and health industry for years to come. Leaders in the food, health, and wellness sectors will need to look ahead on the coming years and plan strategically around these emerging shifts that lie ahead.
Photo Credit: iStock